FDA Introduces Standardized Framework for Gene Therapy Safety
New FDA guidance on evaluating the safety of gene therapies will establish a more predictable development process as these measures are implemented They provide a standardized, layered framework for uncovering off-target effects and other safety issues https://t.co/D7lsBeZybT
Patent‑Free COVID Vaccine Reaches 100 Million at $2‑3
Except the opposite, I make low cost vaccines that actually bypass big pharma, our patent-free COVID vaccine reached 100 million people at $2-3 per dose. It’s sad to see so many give up their critical thinking skills for conspiracy sites,...
AI Models Map Worm Brain, Scale to Synthetic Biology
The C. elegans nervous system has exactly 302 neurons and 7,000 synaptic connections. Scientists have had the full wiring diagram since 1986. What they haven't had: a computational model that captures how those neurons actually develop and wire themselves up. Eric Wasiolek...
Grapefruit Compound Bergamottin Blocks STAT3, Triggers Tumor Cell Death
Bergamottin, a natural furanocoumarin obtained from grapefruit juice induces chemosensitization and apoptosis through the inhibition of STAT3 signaling pathway in tumor cells https://t.co/cLRxHMFBCJ
One Injection Restores Hearing via OTOF Gene Therapy
A single injection uses an engineered AAV virus to deliver a healthy OTOF gene into cochlear cells, enabling them to produce otoferlin and restore the ear’s ability to convert sound vibrations into signals the brain can interpret. https://t.co/Lk34jpnRBe
FDA's 27-Year Freeze Stalled Critical Strep A Vaccine
The FDA accidentally froze Strep A vaccine development for 27 years. @AsimovPress explains what happened and where things stand now, ft. @jacobtrefethen and @coeff_giving's research.
Physics‑Based Sensors and AI Transform Bioreactor Monitoring
Bioreactors are billion-dollar processes monitored by pH probes and dissolved oxygen sensors. That's like running a semiconductor fab with a thermometer. @schmidtsciences is adapting physics tools that don't usually touch biology: fluorescent nanodiamonds, single-cell Raman spectroscopy, and optical frequency combs that...
Targeting Aging: Epigenetic Reprogramming Tackles Disease Root
Aging is arguably the root cause of most major diseases. Our cells lose function as we age, allowing various conditions to manifest, which is why most major diseases correlate with age. Yes, it is more complex than this, but this is...
Low‑cost Vaccines Bypass Big Pharma, Influencers Profit
No, the opposite. I develop low cost vaccines that bypass big pharma. The only shills are those connected to the corrupt wellness influencer industry, which buys whatever it can in bulk cheap so they can jack up the price with...
REPL CEO Skips
$REPL CEO tells me they’re not going to appeal the 2nd CRL but will try to work with FDA - for now, commercial team/other layoffs, cash runway til Q1 of next year, stock price -75% from Fri https://t.co/FLAiOcAAQB
Nasal EV Spray Reverses Neuroinflammation and Boosts Memory
A nasal spray delivering extracellular vesicles reversed neuroinflammation, restored mitochondrial function, and improved memory in aging brain models, suggesting a noninvasive approach to counteract cognitive decline. neuroscience
GLP‑1 Drugs Show Weight‑loss‑independent Benefits, Study Finds
Great work by @DanielJDrucker and team; biologically plausible mechanism of GLP1-RA benefit independent of weight loss. Excellent article by @megtirrell @CNN describing the publication. Could it justify new approaches for these drugs? I think so. https://t.co/pHudk7lkAR
Novo Partners OpenAI as Ideaya's Eye Data Disappoints
Novo teams with OpenAI; Ideaya gets muted response to eye drug data https://t.co/U6sDZlMxyQ $NVO $IDYA $REGN $GSK
Medical Claims Require Trials, Not AI Hype
-AI has nothing to do with it. You are selling bullshit. If your AI can determine which person ‘needs’ which peptide, you will need a trial to show that. -Palantir has nothing to do with it - You can sell...
Comprehensive Genomic Panel Broadens Oncology Treatment Options
Unique Features of a Comprehensive Genomic Profiling Panel: Expanding Treatment Options in a Value-Based Community Oncology Network [Mar 9, 2026] La Porte et al. @DrEzraCohen @JCOPO_ASCO https://t.co/tDi3kbxdvX #PrecisionMedicine #hemeonc @TempusAI https://t.co/zgEw8hfFia
Real-World Data Reveal Molecular Profile of Metastatic ILC
Molecular Characterization of Patients with Metastatic Invasive Lobular Carcinoma: Using Real-World Data to Describe This Unique Clinical Entity [Sep 10, 2025] Davis et al. @CCR_AACR https://t.co/eY0etUfQhQ #bcsm #PrecisionMedicine #camoldx @TempusAI https://t.co/oDkC1Ua6DS
PurIST Classifier Validated for Pancreatic Cancer Therapy
Real-World Validation of the Purity Independent Subtyping of Tumors Classifier for Informing Therapy Selection [PurIST @TempusAI] in Pancreatic Ductal Adenocarcinoma [Sep 4, 2025] @stephwen et al. @JCOPO_ASCO https://t.co/R24DErvaB4 #pancsm #PrecisionMedicine https://t.co/40LqNDQJHo
RUNX1 Identified as Key to Rejuvenate Aging T Cells
Discovery of a factor (RUNX1) that pinpoints T cell senescence and restoring its functionality achieves T cell rejuvenation. Significant implications in older adults with loss of immune system protection. https://t.co/X58DvzIUXY @ImmunityCP https://t.co/hzL3zFiPMm
Continuous Fermentation Cuts Costs, Beats Traditional Bioreactors
The biomanufacturing bottleneck isn't biology. It's economics. Building bigger bioreactors doesn't fix unit costs. https://t.co/2RAcw704uk's bet: continuous fermentation decouples growth from production, keeps cells in an ultra-productive state for weeks, and runs like a conveyor belt instead of a batch process. ...
GLP‑1 Receptors Protect Liver in Mouse MASH Model
Adding to the GLP-1 drug weight-loss independent effect benefit : impact on liver sinusoidal endothelial cell GLP-1 receptors for liver protection in mouse MASH model @Cell_Metabolism @DanielJDrucker @ChusaGzlzRellan https://t.co/0A13QYgm05
Low P‑tau217 Indicates Minimal Alzheimer’s Risk in Seniors
Another study indicative of predictive power of p-tau217 for Alzheimer's disease in cognitively unimpaired older adults (mean age 71 at baseline) A very low p-tau217 denoted minimal risk https://t.co/6RPJcCloWI https://t.co/XikzsvJjhM
In‑vivo Base Editing Rescues Zellweger Disorder in Mice
Today in @natBME we report an in vivo base editing strategy that corrects a common disease-causing mutation and rescues pathology in a mouse model of Zellweger spectrum disorder (ZSD) and restore peroxisomal function in patient derived cells. This work highlights...
Lilly to Acquire CrossBridge Bio in $300 M Deal
NEW: Eli Lilly has agreed to acquire CrossBridge Bio, the Houston-based ADC specialist led by @Mykalt45 I talked with Michael Torres on his run as a first-time CEO ending with a potential $300M deal: https://t.co/PPk3ZWL5SR
Anavex Shows Promise, but EMA Hurdles Loom
Macro: autophagy links autism & Alzheimer’s. Key: Anavex blarcamesine restores autophagy; positive Phase IIb/III data. Risk: EMA pushback. Insight: speculative long, tight stop. 🔬 — Viktor Kopylov, PhD, CFA More insights: t.me/si14Kopylov
TVTX Surges 45% After FDA Approval, Long Calls Lead
$TVTX jumps 45% on FDA approval, always liked this one, continues to work 5K Apr. 32.5 long calls leads the way https://t.co/g7Ga8FIJve
SGLT2 Inhibitors Protect Kidneys, Yet Raise Non‑Renal Risks
Sodium-Glucose Cotransporter-2 Inhibitors and Acute Kidney Injury Risk: A Systematic Review and Meta-Analysis of Randomized Trials "SGLT2is conferred substantial renoprotective benefits but increases the risk of certain nonrenal AEs." https://t.co/n0yhZgcShy
Crossing the SynBio Valley of Death with Proven Solutions
Most synbio companies die between "works in the lab" and "works at scale." Freedom-to-operate issues, process robustness, CMC readiness. The valley of death is real and it swallows good science. @IngenzaLtd has been helping teams cross it for 20 years. Leonardo Magneschi...
Proline‑mediated Dichloromethyl Tagging Enables Ultra‑pure Drug Synthesis
A new method uses the amino acid proline to precisely attach dichloromethyl groups to complex molecules, enabling ultra-pure drug synthesis with built-in quality control and expanding possibilities for advanced medicine design. drugdiscovery
Personal Loss Exposes Danger of Dismissing Cancer Breakthroughs
Hype is bad. That includes calling an unprecedented advance in cancer treatment hype when it is not. Don’t think about the knee jerk comment this tweet is replying to. Think about this man’s wife getting three vacations.
Why Anthropic Chose Coefficient Bio Over Bigger Rivals?
Reading up on the Coefficient Bio deal. I totally get the industrial logic around why Anthropic should care about drug discovery. But why this particular company? There's lots of more scaled players doing this. Can anyone educate me? https://t.co/akFVmRUaYw
DeepSeqAI Trains on Function to Future‑proof Biologics
Most AI protein tools are trained on structure. DeepSeqAI trains on function. They're running billions of experimental protein-protein interactions through their platform to map biologics against viruses, immune receptors, and the entire human proteome. The goal: candidates that hold up against...
CRISPR Turns 25: Explore Its Past, Present, Future
Introducing the GEN Keynote Webinar: "CRISPR at 25: The Past, Present, and Future of Genome Editing" Guest speaker: Rodolphe Barrangou @CRISPRchef May 4, 2026: noon ET/9 am PT Sponsored by @elevatebio https://t.co/cYsSsaod4Y via @GENbio
Merck's $30B Offer Now Exceeds Revolution's Market Cap
Reminder that Merck tried to buy Revolution for $28-$32B (per Jan reporting from FT), vs current market cap after today's great data of $26.5B https://t.co/hoq2P0oiG9
Busy Biotech Day Highlights Promising Advances and Insightful Commentary
As usual, excellent summary by @ldtimmerman @timmermanreport of busy and promising biotech news day - as always delivered w insight and heart (especially thoughtful comments re: revmed drug in context of poignant recent @BenSasse interview)
FDA Zeroes in on Houman Hemmati for CBER Lead
FDA narrows in on search for new biologics and vaccines leader - and we’re hearing @houmanhemmati is a top contender for CBER - https://t.co/qMx8wv32fG
Delaying Generics Boosts Profits Far More than Small Gaps
That gap doesn't look like it could be the largest price-fixing scam in history. it looks like 4% of a generic drug's price. Brand drugs sell for 10-20 times as much as generics, Delaying generic entry by even 6 months...
Off‑the‑Shelf CAR‑T Shows Promise Delaying Lymphoma Relapse
Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphoma https://t.co/UrSNYpQFqB by @gwendolynawu $ALLO + 25%
Pancreatic Cancer Drug Nearly Doubles Survival in Trial
Revolution pancreatic cancer drug nearly doubles survival in key trial https://t.co/SvJicU0LIz @ByJonGardner $RVMD + 38%
AI Company Becomes First Autonomous Drug Prescriber in Utah
An editorial @JAMA_current on @doctronic (the AI company now prescribing renewal medications without physician involvement in Utah) entitled "The First AI Drug Prescriber" https://t.co/Wo1rVhnr4s https://t.co/hAcYbYLmIv
Revolution Medicines' Pancreatic Cancer Drug Shows Late‑Stage Success
This is big. All cancers suck. Pancreatic somehow manages to suck even more. Revolution Medicines says its potential breakthrough pancreatic cancer drug succeeds in late-stage trial https://t.co/rFVsvi0mQD
Multiplexed In‑Vivo Screening Drives Next‑Gen Drug Development
Multiplexed in vivo screening is the future of drug development. @ManifoldBio is multiplexing protein therapies in vivo. @GordianBio is multiplexing gene therapies in vivo. @waypointbio is multiplexing cell therapies in vivo. GT Bio is multiplexing LNPs in vivo. 50Y portcos all https://t.co/DT2AwXbKtB
ALLO May
Has $ALLO found a niche for allo Car-T at last? It's early days, so the answer is maybe. Via @APEXONCO -> https://t.co/bO3A1hpAY8
Rigorous Trials, Not Hype, Prove Cancer Drug Value
Today's $RVMD study outcome in pancreatic cancer is a good lesson for all the $IBRX @DrPatrick fans. Stop with all the hand-waving "cancer cure" podcasting social media nonsense. Shut up and run well-designed clinical trials with definitive endpoints. If you have...
Nanodiscs Reveal Antibody Interactions for HIV, Ebola Vaccines
Nanodisc technology enables viral surface proteins from HIV and Ebola to be studied within lifelike membrane environments, offering new insights into antibody interactions and accelerating the development of next-generation vaccines. vaccinedesign
Pancreatic Cancer Trials Yield Only 1‑2 Month Gains
I remember years ago in pancreatic cancer trials you were realistically looking for 1 to 2 months improvement in survival (at best) in pancreatic cancer trials. Bravo $RVMD.👏
Second‑line RVMD Improves Pancreatic Cancer Survival over First
As noted by others, the $RVMD dara mOS in 2nd line PDAC is better than mOS for current first-line regimens.
Low‑Cost Vaccine Creator Outshines Rogan’s Diet Critique
I make low cost vaccines for global health, including a Covid vaccine technology for $2-3 per dose reached 100 million people, bypassed big pharma, didn’t make money, and all these Rogan types can talk about is a joke I made...
One Gene Therapy Platform Could Cure Obesity and More
Eric Kelsic makes the compelling case on using gene therapy technology to eventually treat common diseases, like obesity: “Fundamentally, we all share the same genetics." Because our bodies run on the same genetic blueprint, a disease - whether common or rare -...
Avalyn Pharma Outlines IPO Fund Allocation, IVVD, REPL Updates
13April: How does Avalyn Pharma plan to spend the proceeds of the IPO for which it has filed paperwork? Read what's been made public about the company's planned initial public offering, plus updates on $IVVD and $REPL in my latest...
Daraxonrasib Halves Pancreatic Cancer Mortality, Doubles Survival
Finally, best news of the morning (and something you didn't expect so soon)... Revolution Medicines $RVMD daraxonrasib Ph3 results in second-line pancreatic cancer. Median overall survival in ITT patients (KRAS mutants + wild type combined) Dara 13.2 months vs chemo 6.7...